Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Equity Income (2021 - 2023)

Intellia Therapeutics (NTLA) has disclosed Equity Income for 3 consecutive years, with -$4.7 million as the latest value for Q4 2023.

  • Quarterly Equity Income fell 45.57% to -$4.7 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$4.7 million through Sep 2024, up 66.59% year-over-year, with the annual reading at -$15.6 million for FY2023, 41.1% down from the prior year.
  • Equity Income for Q4 2023 was -$4.7 million at Intellia Therapeutics, down from -$3.9 million in the prior quarter.
  • The five-year high for Equity Income was -$1.3 million in Q4 2021, with the low at -$4.7 million in Q4 2023.
  • Average Equity Income over 3 years is -$3.1 million, with a median of -$3.2 million recorded in 2022.
  • The sharpest move saw Equity Income tumbled 145.13% in 2022, then decreased 11.04% in 2023.
  • Over 3 years, Equity Income stood at -$1.3 million in 2021, then crashed by 145.13% to -$3.2 million in 2022, then crashed by 45.57% to -$4.7 million in 2023.
  • According to Business Quant data, Equity Income over the past three periods came in at -$4.7 million, -$3.9 million, and -$4.0 million for Q4 2023, Q3 2023, and Q2 2023 respectively.